The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
5 Things You Need to Know About Epilepsy & Depression
5 Things You Need to Know About Epilepsy & Depression
How Much Should We Worry About Amyloid-Related Imaging Abnormalities?
How Much Should We Worry About Amyloid-Related Imaging Abnormalities?
How Should We Monitor Patients on Amyloid-Targeting Therapy?
How Should We Monitor Patients on Amyloid-Targeting Therapy?
What’s the Best Way to Identify Mild Cognitive Impairment and Early Alzheimer’s Disease?
What’s the Best Way to Identify Mild Cognitive Impairment and Early Alzheimer’s Disease?
How Do You Counsel Patients About Amyloid-Related Imaging Abnormalities?
How Do You Counsel Patients About Amyloid-Related Imaging Abnormalities?
What is the Role of APOE4 Testing in Alzheimer’s Disease?
What is the Role of APOE4 Testing in Alzheimer’s Disease?
Which Biomarkers Do You Recommend to Confirm Amyloid Positivity?
Which Biomarkers Do You Recommend to Confirm Amyloid Positivity?
What Types of Changes, If Any, Should We Expect with Amyloid-Targeting Therapy?
What Types of Changes, If Any, Should We Expect with Amyloid-Targeting Therapy?